Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001104659-24-100991
Filing Date
2024-09-18
Accepted
2024-09-18 16:38:44
Documents
11
Period of Report
2024-09-18

Document Format Files

Seq Description Document Type Size
1 FORM 6-K tm2423681d8_6k.htm 6-K 11432
2 EXHIBIT 1.1 tm2423681d8_ex1-1.htm EX-1.1 248939
3 EXHIBIT 4.1 tm2423681d8_ex4-1.htm EX-4.1 81272
4 EXHIBIT 4.2 tm2423681d8_ex4-2.htm EX-4.2 80942
5 EXHIBIT 4.3 tm2423681d8_ex4-3.htm EX-4.3 77979
6 EXHIBIT 4.3 tm2423681d8_ex4-4.htm EX-4.3 78226
7 EXHIBIT 4.5 tm2423681d8_ex4-5.htm EX-4.5 25928
8 EXHIBIT 5.1 tm2423681d8_ex5-1.htm EX-5.1 12903
9 EXHIBIT 5.2 tm2423681d8_ex5-2.htm EX-5.2 49359
10 GRAPHIC tm2423681d8_ex1-1img001.jpg GRAPHIC 5390
11 GRAPHIC tm2423681d8_ex5-2img001.gif GRAPHIC 1926
  Complete submission text file 0001104659-24-100991.txt   678247
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Filer) CIK: 0001114448 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-15024 | Film No.: 241308021
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)